Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121501 | 0.92 | ACHE (0.38) | ACHE | |
| SCHEMBL4122116 | 0.88 | GPR119 (0.46) | GPR119MMP13USP30FAAH | |
| SCHEMBL4115144 | 0.87 | GPR119 (0.41) | GPR119KDM4EPKMFAAHALOX5AP | |
| SCHEMBL4112457 | 0.86 | TGFBR1 (0.41) | GPR119KDM4EPKMFAAHADORA2A | |
| SCHEMBL4126892 | 0.86 | TGFBR1 (0.39) | GPR119KDM4EPKMFAAHADORA2A | |
| SCHEMBL4120553 | 0.86 | GPR119 (0.38) | GPR119KDM4EPKMFAAHACHE | |
| SCHEMBL4120303 | 0.84 | GPR119 (0.39) | GPR119KDM4EPKMFAAHACHE | |
| SCHEMBL4120349 | 0.83 | GPR119 (0.43) | GPR119MMP13KDM4EPKMUSP30 | |
| SCHEMBL4127069 | 0.83 | GPR119 (0.36) | GPR119KDM4EPKMFAAHACHE | |
| Dimethylamine SCHEMBL4122103 | 0.83 | GPR119 (0.42) | GPR119MMP13KDM4EPKMUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | GPR119 122/4885MMP13 2610/4885KDM4E 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.